Corinne Johnson
Stock Analyst at Goldman Sachs
(3.26)
# 1,004
Out of 5,169 analysts
15
Total ratings
57.14%
Success rate
16.91%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Corinne Johnson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TGTX TG Therapeutics | Maintains: Neutral | $37 → $39 | $30.04 | +29.83% | 1 | Jan 15, 2026 | |
| IMVT Immunovant | Maintains: Neutral | $18 → $28 | $23.60 | +18.64% | 2 | Dec 15, 2025 | |
| MBX MBX Biosciences | Initiates: Sell | $18 | $28.70 | -37.28% | 1 | Dec 4, 2025 | |
| AMLX Amylyx Pharmaceuticals | Maintains: Buy | $10 → $20 | $13.79 | +45.03% | 2 | Sep 16, 2025 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $20 → $24 | $23.65 | +1.48% | 2 | Sep 5, 2025 | |
| AVBP ArriVent BioPharma | Reinstates: Buy | $33 | $22.81 | +44.67% | 3 | Jul 10, 2025 | |
| NBIX Neurocrine Biosciences | Initiates: Buy | $182 | $130.71 | +39.24% | 1 | Jul 10, 2025 | |
| CGON CG Oncology | Upgrades: Buy | $43 → $50 | $64.45 | -22.42% | 3 | May 14, 2024 |
TG Therapeutics
Jan 15, 2026
Maintains: Neutral
Price Target: $37 → $39
Current: $30.04
Upside: +29.83%
Immunovant
Dec 15, 2025
Maintains: Neutral
Price Target: $18 → $28
Current: $23.60
Upside: +18.64%
MBX Biosciences
Dec 4, 2025
Initiates: Sell
Price Target: $18
Current: $28.70
Upside: -37.28%
Amylyx Pharmaceuticals
Sep 16, 2025
Maintains: Buy
Price Target: $10 → $20
Current: $13.79
Upside: +45.03%
Syndax Pharmaceuticals
Sep 5, 2025
Maintains: Buy
Price Target: $20 → $24
Current: $23.65
Upside: +1.48%
ArriVent BioPharma
Jul 10, 2025
Reinstates: Buy
Price Target: $33
Current: $22.81
Upside: +44.67%
Neurocrine Biosciences
Jul 10, 2025
Initiates: Buy
Price Target: $182
Current: $130.71
Upside: +39.24%
CG Oncology
May 14, 2024
Upgrades: Buy
Price Target: $43 → $50
Current: $64.45
Upside: -22.42%